Protalix Biotherapeutics, Inc. (PLX) — SEC Filings
Protalix Biotherapeutics, Inc. (PLX) — 24 SEC filings. Latest: 10-Q (Nov 13, 2025). Includes 11 8-K, 6 10-Q, 2 DEF 14A.
View Protalix Biotherapeutics, Inc. on SEC EDGAR
Overview
Protalix Biotherapeutics, Inc. (PLX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 13, 2025: Protalix BioTherapeutics, Inc. reported a net loss of $1.1 million for the nine months ended September 30, 2025, a significant improvement from the $3.56 million net loss in the same period of 2024. Total revenue for the nine-month period increased to $43.62 million in 2025 from $35.18 million in 20
Sentiment Summary
Across 24 filings, the sentiment breakdown is: 1 bearish, 21 neutral, 2 mixed. The dominant filing sentiment for Protalix Biotherapeutics, Inc. is neutral.
Filing Type Overview
Protalix Biotherapeutics, Inc. (PLX) has filed 6 10-Q, 11 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G/A, 1 DEFA14A with the SEC between Jan 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (24)
Risk Profile
Risk Assessment: Of PLX's 21 recent filings, 0 were flagged as high-risk, 10 as medium-risk, and 11 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $43.62M |
| Net Income | -$1.1M |
| EPS | -$0.01 |
| Debt-to-Equity | 0.55 |
| Cash Position | $13.65M |
| Operating Margin | -1.9% |
| Total Assets | $82.26M |
| Total Debt | $29.36M |
Key Executives
- Eyal Rubin
Industry Context
Protalix BioTherapeutics operates in the competitive biopharmaceutical sector, focusing on rare and orphan diseases. The industry is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and effective commercialization strategies. Key trends include advancements in protein-based therapeutics and a growing demand for treatments for underserved patient populations.
Top Tags
financials (5) · corporate-governance (5) · Biotechnology (4) · filing (4) · 10-Q (4) · biotech (4) · SEC Filing (3) · Rare Diseases (2) · Fabry Disease (2) · Gaucher Disease (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss | $1.1M | for the nine months ended September 30, 2025, improved from $3.56M loss in 2024 |
| Total Revenue | $43.62M | for the nine months ended September 30, 2025, up from $35.18M in 2024 |
| Research and Development Expenses | $13.93M | for the nine months ended September 30, 2025, up from $8.85M in 2024 |
| Cash and Cash Equivalents | $13.65M | as of September 30, 2025, down from $19.76M at December 31, 2024 |
| Common Stock Available for Sale | $15.7M | under the Sales Agreement as of September 30, 2025 |
| Shares Outstanding | 80,421,181 | as of November 1, 2025 |
| Net Income | $2.36M | for the three months ended September 30, 2025, down from $3.24M in 2024 |
| Proceeds from Stock Issuance | $6.81M | under Sales Agreement for nine months ended September 30, 2025 |
| Proceeds from Warrants and Options Exercise | $2.42M | for nine months ended September 30, 2025 |
| Total Revenue (H1 2025) | $25.77M | Increased 49.6% from $17.22 million in H1 2024 |
| Total Revenue (Q2 2025) | $15.66M | Increased from $13.47 million in Q2 2024 |
| Net Income (Q2 2025) | $0.16M | Turnaround from a $2.20 million net loss in Q2 2024 |
| Net Loss (H1 2025) | $3.46M | Improved from a $6.80 million net loss in H1 2024 |
| R&D Expenses (H1 2025) | $9.47M | Increased from $5.85 million in H1 2024 |
| Cash and Cash Equivalents (June 30, 2025) | $17.90M | Decreased from $19.76 million at December 31, 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Protalix Biotherapeutics, Inc. (PLX)?
Protalix Biotherapeutics, Inc. has 24 recent SEC filings from Jan 2024 to Nov 2025, including 11 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PLX filings?
Across 24 filings, the sentiment breakdown is: 1 bearish, 21 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Protalix Biotherapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Protalix Biotherapeutics, Inc. (PLX) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Protalix Biotherapeutics, Inc.?
Key financial highlights from Protalix Biotherapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PLX?
The investment thesis for PLX includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Protalix Biotherapeutics, Inc.?
Key executives identified across Protalix Biotherapeutics, Inc.'s filings include Eyal Rubin.
What are the main risk factors for Protalix Biotherapeutics, Inc. stock?
Of PLX's 21 assessed filings, 0 were flagged high-risk, 10 medium-risk, and 11 low-risk.
What are recent predictions and forward guidance from Protalix Biotherapeutics, Inc.?
Forward guidance and predictions for Protalix Biotherapeutics, Inc. are extracted from SEC filings as they are enriched.